Monoxyde D’azote Sol France (Nitric Oxide)

Nitric Oxide, the active ingredient in Monoxyde D’azote Sol France, is an inhaled nitric oxide presented as a gas for inhalation use. It treats pulmonary hypertension, neonatal respiratory distress syndrome, and acute respiratory distress syndrome by selectively dilating pulmonary vessels.

GNH USA supplies Monoxyde D’azote Sol France as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and clinics worldwide.

Nitric oxide is used as a selective pulmonary vasodilator in disorders of the pulmonary circulation.

Pulmonary hypertension: reduces pulmonary arterial pressure and improves oxygenation. Neonatal respiratory distress syndrome: enhances oxygenation and decreases need for extracorporeal support. Acute respiratory distress syndrome: improves ventilation‑perfusion matching and lowers pulmonary vascular resistance.

Adverse reactions may occur with inhaled nitric oxide therapy.

Common Side Effects: - Methemoglobinemia: elevation of methemoglobin levels causing reduced oxygen delivery. - Nitrogen dioxide formation: irritant gas that can damage airway epithelium. - Systemic hypotension: mild drop in systemic blood pressure. - Cough or throat irritation during inhalation.

Serious or Rare Side Effects: - Severe hypotension leading to hemodynamic instability. - Rebound pulmonary hypertension after abrupt discontinuation. - Bleeding complications in patients with coagulopathy. - Neurotoxicity manifested as seizures in rare cases.

Key safety considerations should be observed when using inhaled nitric oxide. - Methemoglobin monitoring: regularly assess levels to avoid toxicity. - Dose adjustment in neonates: use the lowest effective concentration. - Avoid concurrent use with other potent pulmonary vasodilators without supervision. - Ensure proper ventilation to limit nitrogen dioxide accumulation. - Store at ambient temperature: keep cylinders in original packaging, protect from heat and direct sunlight.

Potential drug interactions require careful management.

Major Interactions (Avoid): - Concurrent pulmonary vasodilators (e.g., sildenafil, bosentan): may cause profound hypotension. - Other nitric oxide donors: additive vasodilatory effect can precipitate severe hypotension.

Moderate Interactions (Monitor Closely): - Inhaled anesthetics (e.g., sevoflurane): may enhance vasodilatory response. - Phosphodiesterase‑5 inhibitors: may increase cGMP levels, requiring dose titration. - Anticoagulants: monitor for bleeding if pulmonary pressures change rapidly.